BioTelemetry (NASDAQ: BEAT) and Cannabis Science (OTCMKTS:CBIS) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, institutional ownership and profitability.

Valuation and Earnings

This table compares BioTelemetry and Cannabis Science’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
BioTelemetry $208.33 million 4.17 $53.43 million $1.29 20.78
Cannabis Science N/A N/A N/A N/A N/A

BioTelemetry has higher revenue and earnings than Cannabis Science.

Profitability

This table compares BioTelemetry and Cannabis Science’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
BioTelemetry 16.10% 13.66% 8.44%
Cannabis Science -953,196.00% N/A -380.46%

Volatility and Risk

BioTelemetry has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, Cannabis Science has a beta of -3.62, indicating that its stock price is 462% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for BioTelemetry and Cannabis Science, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioTelemetry 1 0 7 0 2.75
Cannabis Science 0 0 0 0 N/A

BioTelemetry currently has a consensus price target of $43.50, suggesting a potential upside of 62.31%. Given BioTelemetry’s higher probable upside, equities research analysts plainly believe BioTelemetry is more favorable than Cannabis Science.

Insider and Institutional Ownership

82.2% of BioTelemetry shares are held by institutional investors. 9.6% of BioTelemetry shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

BioTelemetry beats Cannabis Science on 9 of the 9 factors compared between the two stocks.

BioTelemetry Company Profile

BioTelemetry, Inc. (BioTelemetry), formerly CardioNet, Inc., provides cardiac monitoring services, cardiac monitoring device manufacturing, and centralized cardiac core laboratory services. The Company operates in three segments: patient services, product and research services. The patient services business segment’s principal focus is on the diagnosis and monitoring of cardiac arrhythmias or heart rhythm disorders, through its core Mobile Cardiac Outpatient Telemetry(MCOT), event and Holter services in a healthcare setting. The product business segment focuses on the development, manufacturing, testing and marketing of medical devices to medical companies, clinics and hospitals. The Company’s research services focuses on providing cardiac safety monitoring services for drug and medical treatment trials in a research environment. In August 2012, the Company completed the acquisition of Cardiocore Lab, Inc. (Cardiocore).

Cannabis Science Company Profile

Cannabis Science, Inc. is engaged in medical marijuana research and development. The Company works on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce and commercialize phytocannabinoid-based pharmaceutical products. The Company is involved in the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company focuses on the development of governmentally approved pharmaceuticals, including CS-TATI1, CS-S/BCC-1 and neurological therapy under study or development. The Company’s subsidiaries include Cannabis Science BV and Cannabis Science International Holding BV.

Receive News & Ratings for BioTelemetry Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTelemetry Inc. and related companies with MarketBeat.com's FREE daily email newsletter.